Celgene Corp. had another double-digit growth year and expects sales spikes to continue for the next several years. Driving that view is existing blockbusters as well as mid- to late-stage research and development programs, many of which the company highlighted in its Jan. 26 earnings report.
Celgene is one of the most transparent public biopharmaceutical companies in terms of financial projections for the near, mid- and...